Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

CompletedOBSERVATIONAL
Enrollment

44

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

December 28, 2022

Study Completion Date

May 5, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
BIOLOGICAL

Elizaria®

Elizaria® will be prescribed by the Physician according to the actual SMPC.

Trial Locations (8)

125284

State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin of the Moscow Department of Health, Moscow

185019

"State budgetary institution of health care of the Republic of Karelia Republican hospital named after V.A. Baranov ", Petrozavodsk

344015

"State budgetary institution of the Rostov region Rostov Regional Clinical Hospital", Rostov-on-Don

443099

"Federal State Budgetary Educational Institution of Higher Education Samara State Medical University of the Ministry of Health of the Russian Federation", Samara

454076

"State budgetary healthcare institution Chelyabinsk Regional Clinical Hospital", Chelyabinsk

620102

"State Budgetary Healthcare Institution of the Sverdlovsk Region Sverdlovsk Regional Clinical Hospital No. 1", Yekaterinburg

630091

"Federal State Budgetary Educational Institution of Higher Education Novosibirsk State Medical University of the Ministry of Health of the Russian Federation on the basis of the State Budgetary Institution of Health of the Novosibirsk Region City Clinic", Novosibirsk

644079

"State Budgetary Institution of Healthcare Irkutsk Order of the Badge of Honor Regional Clinical Hospital", Irkutsk

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT04671810 - Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® | Biotech Hunter | Biotech Hunter